

Potential drug metabolites as endocannabinoids and endovanilloids



Sinning, C.¹, De Petrocellis, L.², Cascio, M.G.³, Di Marzo, V.³, Imming, P.¹

¹ Institut für Pharmazie, Martin-Luther-Universität, Wolfgang-Langenbeck-Str. 4, 06120 Halle, Germany


² Istituto di Cibernetica, CNR, Via Campi Flegrei 34, 80078 Pozzuoli, Italy

³ Istituto di Chimica Biomolecolare, CNR, Via Campi Flegrei 34, 80078 Pozzuoli, Italy

1. Introduction


Δ^9 -Tetrahydrocannabinol is the most famous plant-derived cannabinoid. Recently, N-arachidonoyl-ethanolamine (**1**, anandamide) and N-arachidonoyl-dopamine (**2**) were discovered as endogenous ligands of G-protein coupled receptors addressed by Δ^9 -tetrahydrocannabinol [1], [2]. The arachidonic acid derivatives bind to cannabinoid receptors (CB₁ and CB₂), are degraded by fatty acid amide hydrolase (FAAH), are supposed to be transported inside cells by the anandamide transporter and interact with the vanilloid receptor 1 (TRPV1, a ligand gated Ca²⁺ channel). Due to their physiological activities these compounds are called endocannabinoids and endovanilloids.

We hypothesise that the activities of some known drug substances are partly effected by acyl metabolites. Here we present the synthesis of three potential drug metabolites generated by replacement of either the amine or the acid moiety in **1** or **2** along with the results of in vitro assays with CB₁, CB₂, and TRPV1 receptors and the putative anandamide transporter.




2. Synthesis and analysis

1. Arachidonic acid mesalazine amide (**3**)



2. Flufenamic (**4**) and mefenamic acid (**5**) dopamide






Analytical confirmation: ¹H-, ¹³C-NMR, EI-MS, combustion analysis

5. TRPV1 assay

Assay procedure: HEK-293 cells transfected with human TRPV1 were used in the experiments. The effect of the compounds on Ca²⁺ influx was determined by using Fluo-4, a selective intracellular fluorescent probe for Ca²⁺. Experiments were carried out by measuring cell fluorescence at 25 °C (λ_{EX} : 488 nm, λ_{EM} : 516 nm) before and after the addition of the test compounds at various concentrations. The efficacy of the agonists was determined by comparing to the maximal effect on Ca²⁺ influx observed with 4 μ M ionomycin, whereas antagonistic behaviour was evaluated by the reduction of Ca²⁺ influx provoked with 0.1 μ M capsaicin (EC₅₀ = 51 nM) [4].

Data points are means of n = 3 experiments:



6. Outlook

Anandamide transporter inhibitors are known to be effective in animal models of inflammatory bowel diseases [5]. So does **3** take part in the mechanism of action of mesalazine just as the anandamide transporter inhibitor N-arachidonoyl-phenolamine (AM404) does with paracetamol [6]? It was shown that the analgesic activity of paracetamol was abolished by CB₁ antagonists in rats [7]. Again, application of TRPV1 agonists like capsaicin or **4** and **5** elicits an effect called desensitisation that may be useful regarding analgesia [8]. TRPV1 antagonists should avoid neurotoxicity due to Ca²⁺ overload while retaining analgesic properties. Are **4** and **5** suitable templates for the development of high-affinity antagonists?

One gripping question remains: Do these potential drug metabolites really occur in vivo? We will try to answer this question especially in case of compound **3** by LC-MS analysis of suitable human tissue.

3. Transporter assay

Assay procedure: The effect on the uptake of [¹⁴C]-**1** by intact RBL-2H3 cells was studied by using 5.0 μ M (20,000 cpm) of [¹⁴C]-**1**. Cells were incubated with [¹⁴C]-**1** for 5 min at 37 °C, in the presence or absence of **3** at a concentration of 25 μ M. Residual [¹⁴C]-**1** in the incubation media after extraction with CHCl₃/CH₃OH (2:1), determined by scintillation counting of the lyophilized organic phase, was used as a measure of the [¹⁴C]-**1** that was taken up by cells.

3 inhibited 80 % of [¹⁴C]-**1** uptake at 25 μ M. It is thus approximately equipotent with the established anandamide transporter inhibitor VDM-11 (IC₅₀: 10 μ M) [3].

4. CB receptors assay

Assay procedure: For CB₁ and CB₂ receptor binding assays, the compounds were analyzed by using HEK-293 cells transfected stably with either the human CB₁ or CB₂ receptor and [³H]CP-55,940 as the high-affinity ligand. WIN 55,212-2 was used to define specific binding in the assay. All experiments took place in the absence of a FAAH inhibitor.

Rates of displacement:

	1 μ M -CB ₁ -	10 μ M -CB ₁ -	1 μ M -CB ₂ -	10 μ M -CB ₂ -
3	32 %	64 %	12 %	29 %
4	31 %	100 %	13 %	73 %
5	21 %	67 %	3 %	34 %

7. Literature

- [1] Devane, W. A. et al. (1992) Science 258: 1946-9
- [2] Huang, S. M. et al. (2002) Proc. Natl. Acad. Sci. 99: 8400-5
- [3] De Petrocellis, L. et al. (2000) FEBS Letters 483: 52-6
- [4] Smart, D. et al. (2001) Eur. J. Pharmacol. 417: 51-8
- [5] D'Argenio et al. (2006) FASEB J. doi: 10.1096/fj.05-4943fje.
- [6] Högestätt, E. D. et al. (2005) J. Biol. Chem. 280: 31405-12
- [7] Ottani, A. et al. (2006) Eur. J. Pharmacol. 531: 280-1
- [8] Szallasi, A. et al. (2004) J. Med. Chem. 47: 2717-23

8. Acknowledgment

This work was supported by a scholarship from the Lesmüller-Stiftung to C.S.